Ionis Presents New Data from NEURO-TTR Study and Highlights Programs from Its Neurological Disease Franchise at ANA Congress

Inotersen treatment resulted in a 20-point benefit in mNIS+7 compared to placebo Ionis antisense programs featured in 11 platform and poster presentations at ANA CARLSBAD, Calif., Oct. 15, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that new data from the Phase 3 NEURO-TTR study with inotersen in patients with hereditary TTR amyloidosis (hATTR) with polyneuropathy were presented at the 142nd annual meeting of the American Neurological Association (ANA) in San Diego, California. In the study, inotersen-treated patients achieved a mean 19.73-point benefit in the mNIS+7 co-primary endpoint after 15 months of treatment, compared to placebo-treated patients (p = 0.00000004), further demonstrating the clinically meaningful benefit of inotersen treatment. A statistically significant benefit in mNIS+7 was also observed at eight months. Key safety findings of thrombocytopenia and renal events identified during the study were shown to be monitorable and manageable with routine blood and urine testing. Multiple other innovative drugs from Ionis' portfolio of drugs for patients with serious neurological and neurodegenerative diseases will be highlighted as part of the Antisense Oligonucleotide Treatment of Genetic Neurological Diseases plenary session on Tuesday, October 17.

The release as fetched from its publisher. ionis.com ↗